Printer Friendly

REPROS' PROMISING DRUG PIPELINE

Little- known Repros Therapeutics (RPRX) is expected to team up with a big drugmaker to help develop its lead product, Proellex, now in Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the , to treat uterine fibroids Uterine Fibroids Definition

Uterine fibroids (also called leiomyomas or myomas) are benign growths of the muscle inside the uterus. They are not cancerous, nor are they related to cancer.
 and related anemia--a $3 billion market. Each year "some 300,000 women in the U.S. undergo hysterectomy hysterectomy (hĭstərĕk`təmē), surgical removal of the uterus. A hysterectomy may involve removal of the uterus only or additional removal of the cervix (base of the uterus), fallopian tubes (salpingectomy), and ovaries  as a result of uterine fibroids," notes Mark Lappe, managing partner at Efficacy Capital, which owns shares. Repros is also developing Androxal, now in Phase II trials, to restore pituitary pituitary /pi·tu·i·tary/ (pi-too´i-tar?e)
1. hypophysial.

2. pituitary gland; see under gland.


anterior pituitary  adenohypophysis.
 response in men with low testosterone levels, and for obese people with high blood pressure and diabetes. Lappe says 13 million men in the U.S. have testosterone deficiency. Oppenheimer analyst Dr. Brian Abrahams rates Repros, now at 9.64, outperform with a 12-month target of 19. "Proellex could fill an unmet need in treating fibroids Fibroids
Benign tumors of muscle and connective tissue that develop within or are attached to the uterine wall.

Mentioned in: Menstrual Disorders
," he says.



Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.

Copyright 2008 BusinessWeek
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright (c) Mochila, Inc.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Author:Gene Marcial
Publication:BusinessWeek
Date:Apr 3, 2008
Words:166
Previous Article:DON'T BE LEERY OF LEHMAN
Next Article:GETTING ALARMED OVER THE 'R WORD'


Related Articles
NeoTherapeutics receives patent for purine-based technology.
More promise. (Letters).
BIOLINERX LICENSES PEPTIDE FOR INFLAMMATORY DISEASES.
BIOLINERX/UNIVERSITY OF ILLINOIS TO DEVELOP APOPTOSIS AGENT.
Repros Provides Update for Regulatory Program Associated with Androxal Development.
BIOLINERX IN-LICENSES NOVEL DRUG FOR ACUTE KIDNEY INJURY.
Fast Forward[TM]: more treatments, faster.
Moving research Fast Forward.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters